|
市場調査レポート
商品コード
1401018
バイオエレクトリック医療の世界市場規模、シェア、産業動向分析レポート:タイプ別、最終用途別、製品別、用途別、地域別展望と予測、2023年~2030年Global Bioelectric Medicine Market Size, Share & Industry Trends Analysis Report By Type, By End-use, By Product, By Application, By Regional Outlook and Forecast, 2023 - 2030 |
||||||
バイオエレクトリック医療の世界市場規模、シェア、産業動向分析レポート:タイプ別、最終用途別、製品別、用途別、地域別展望と予測、2023年~2030年 |
出版日: 2023年12月21日
発行: KBV Research
ページ情報: 英文 372 Pages
納期: 即納可能
|
バイオエレクトリック医療の市場規模は2030年までに317億米ドルに達すると予測され、予測期間中のCAGRは6.1%の市場成長率で上昇する見込みです。
KBV Cardinalのマトリックスに掲載された分析によると、Abbott LaboratoriesとMedtronic PLCが市場の先行者です。2021年11月、メドトロニックPLCは、集約された脳データを用いて神経疾患や精神疾患のための精密医薬品の開発と提供を強化するRune Labs社と提携しました。この提携は、脳信号を慢性的に捕捉・記録できる最初で唯一の完全な脳深部刺激システムであるブレインセンス技術の使用を評価することを目的としています。Boston Scientific Corporation、Nevro Corporation、electroCore, Inc.などの企業が、この市場における主要なイノベーターです。
COVID-19影響分析
パンデミックは世界のサプライチェーンを混乱させ、バイオエレクトリック装置や部品の生産と流通に影響を与えました。ロックダウン、渡航制限、労働力の課題が製造と供給の遅れにつながり、特定のバイオエレクトリック技術の入手可能性に影響を与えました。市場の多くの研究開発活動は、研究所が一時的に閉鎖され、資源がCOVID-19関連の研究に振り向けられたため、遅れが生じました。新しいバイオエレクトリック療法の臨床試験は中断に直面し、製品開発のスケジュールに影響を与えました。そのため、COVID-19の流行は市場に悪影響を及ぼしました。
市場成長要因
世界の高齢化人口の増加
加齢プロセスは、心血管障害、神経変性疾患(アルツハイマー病やパーキンソン病など)、関節炎、その他の加齢関連疾患などの慢性疾患のリスク増大と関連しています。バイオエレクトリック的介入は,生理学的プロセスを調節する可能性を通して,これらの状態を効果的に管理し治療するための新しいアプローチを提供することができます。バイオエレクトリック医療は病気の治療だけでなく,全体的な生活の質を高めることも目的としています。神経調節やその他の技術を含むバイオエレクトリック的介入は、これらの側面を改善し、高齢者の生活の質の向上を促進することができます。こうした要因が市場の拡大に寄与すると思われます。
研究開発投資の増加
研究への投資は、承認と商業化のための規制当局の経路をナビゲートするのに役立ちます。規制基準を満たすことは、バイオエレクトリック療法を市場に投入する上で極めて重要であり、継続的な投資は、これらの要件を満たすために必要な研究や文書化をサポートします。業界のリーダーたちのリソースの投入は、市場の拡大に貢献します。新しい治療法が開発され、その有効性が証明されれば、より広範な患者集団に届けることができ、市場への浸透が高まります。したがって、これらの要因は市場に有利な成長見通しをもたらすと思われます。
市場抑制要因
薬事承認に関する課題
製品を国際的に販売しようとするバイオエレクトリック企業は、複数の規制の枠組みを乗りこなすという課題に直面しています。地域間の承認プロセスや要件の違いは、全体的な規制のタイムラインに複雑さと長さを加える可能性があります。規制機関は、急速に進化する生物電気医学の技術に対応するために既存の枠組みを適応させるという課題に直面するかもしれません。いくつかのバイオエレクトリック療法の新規性と独自性により、規制機関は専門的なガイドラインを開発する必要があるかもしれないです。これらの要素は市場の成長を妨げるでしょう。
タイプ別展望
タイプ別に見ると、市場は埋め込み型電気治療器と非侵襲型電気治療器に二分されます。2022年には、非侵襲性電気治療機器セグメントが市場で大きな収益シェアを占める。非侵襲的電気治療機器は、侵襲的処置に代わる患者に優しい代替手段を提供します。痛みの軽減、不快感の最小化、外科的介入を行わないことから、患者はしばしば非侵襲的治療を好みます。このアプローチは患者のコンプライアンスを高め、前向きな患者体験に貢献します。洗練された非侵襲的電気治療装置の開発には、技術の進歩が不可欠です。経皮的電気刺激や非侵襲的神経調節などの革新的技術は、非侵襲的介入の範囲を拡大しています。したがって、この分野は今後数年で急速に拡大すると思われます。
最終用途の展望
最終用途別に見ると、市場は病院とその他に分けられます。病院セグメントは2022年の市場で最大の収益シェアを記録しました。バイオエレクトリック介入は、神経学や疼痛管理から心臓病学やリハビリテーションに至るまで、様々な医療専門分野にわたって応用を見出しています。バイオエレクトリック療法の多用途性により、多様な病状に対応することが可能になり、病院は様々な部門においてこれらの介入を模索し、実施するようになっています。したがって、これらの要因が病院セグメントの成長を促進します。
製品展望
製品は、植込み型除細動器・心臓ペースメーカー、人工内耳、脊髄刺激装置、脳深部刺激装置、経皮的電気神経刺激装置、仙骨・迷走神経刺激装置、その他に区分されます。2022年には、脊髄刺激装置セグメントが市場で大きな収益シェアを獲得しました。脊髄刺激装置は、腰痛手術失敗症候群や複合性局所疼痛症候群などの慢性疼痛状態を管理するための治療オプションとして使用されることが多いです。これらの疾患の有病率の上昇は、高齢化人口の増加と相まって、脊髄刺激装置に対する需要の増加に寄与する可能性があります。したがって、この分野は今後数年で急速に拡大すると思われます。
用途別展望
用途別に見ると、市場は不整脈、疼痛管理、感音性難聴、パーキンソン病、振戦・てんかん、うつ病、治療抵抗性うつ病、尿失禁・便失禁、その他に分けられます。2022年には、振戦・てんかん分野が市場で大きな収益シェアを占めました。振戦とてんかんは、しばしば脳内の異常な電気活動を伴う。バイオエレクトリック医療の重要な要素である神経調節療法は、神経活動を調節するために電気刺激を使用します。神経調節技術の進歩は、振戦やてんかんのような疾患に対して、より効果的な治療法につながる可能性があります。これらの要因によって、この分野は急速に拡大することが予想されます。
地域別展望
地域別に見ると、市場は北米、欧州、アジア太平洋、LAMEAに区分されます。北米セグメントは、2022年の市場で最も高い収益シェアを獲得しました。北米、特に米国はヘルスケア産業において重要な役割を担っており、医療技術やイノベーション産業が堅調です。この地域は、バイオエレクトリック医療の研究開発の最前線にあります。学術機関、研究センター、業界とのコラボレーションがイノベーションを促進し、新しいバイオエレクトリック療法やデバイスの開発につながることが多いです。従って、このセグメントは今後数年で成長することが予想されます。
The Global Bioelectric Medicine Market size is expected to reach $31.7 billion by 2030, rising at a market growth of 6.1% CAGR during the forecast period.
Deep brain stimulation (DBS) is a well-established technique involving implanted electrodes to deliver electrical impulses to specific brain regions, providing therapeutic benefits in conditions like Parkinson's disease. Therefore, Deep Brain Stimulators segment generated $1,022.1 million revenue in the market in 2022. Likewise, neuromodulation techniques, such as transcranial magnetic stimulation (TMS), and deep brain stimulation, are being explored for their potential in various neurological and psychiatric disorders. These techniques aim to modulate neural activity to restore normal functioning and alleviate symptoms. These aspects will lead to increased demand in the market.
The major strategies followed by the market participants are Partnerships, Collaborations & Agreements as the key developmental strategy to keep pace with the changing demands of end users. For instance, In August, 2021, electroCore, Inc. signed an agreement with Red One Medical Devices, LLC, a service-disabled veteran-owned small business. This agreement aimed to widen the availability of electroCore's gammaCore platform in the federal marketplace. Moreover, In May, 2020, Medtronic collaborated with UW following which the company has accelerated research into deep brain stimulation treatment for essential tremor, Parkinson's disease, and other neurological disorders.
Based on the Analysis presented in the KBV Cardinal matrix; Abbott Laboratories and Medtronic PLC are the forerunners in the Market. In November, 2021, Medtronic PLC partnered with Rune Labs, a company using aggregated brain data to empower the development and delivery of precision medicines for neurological and psychiatric diseases. This partnership aimed to assess the use of BrainSense technology, the first and only complete Deep Brain Stimulation system able to chronically capture and record brain signals. Companies such as Boston Scientific Corporation, Nevro Corporation and electroCore, Inc. are some of the key innovators in the Market.
COVID-19 Impact Analysis
The pandemic disrupted global supply chains, affecting the production and distribution of bioelectric devices and components. Lockdowns, travel restrictions, and workforce challenges led to delays in manufacturing and supply, impacting the availability of certain bioelectric technologies. Many research and development activities in the market experienced delays as laboratories were temporarily closed, and resources were redirected toward COVID-19-related research. Clinical trials for new bioelectric therapies faced interruptions, affecting timelines for product development. Therefore, the COVID-19 pandemic led to a negative impact on the market.
Market Growth Factors
Growing aging population globally
The aging process is associated with an increased risk of chronic diseases such as cardiovascular disorders, neurodegenerative conditions (like Alzheimer's and Parkinson's diseases), arthritis, and other age-related ailments. Bioelectric interventions, through their potential to modulate physiological processes, can offer novel approaches to manage and treat these conditions effectively. Bioelectric medicine aims not only to treat diseases but also to enhance the overall quality of life. Bioelectric interventions, including neuromodulation and other techniques, can improve these aspects and promote a better quality of life for elderly individuals. These factors will help in the expansion of the market.
Rising investments in research and development
Investment in research helps navigate regulatory pathways for approval and commercialization. Meeting regulatory standards is crucial for bringing bioelectric therapies to the market, and ongoing investment supports the necessary studies and documentation to meet these requirements. The commitment of resources from industry leaders contributes to expanding the market. As new therapies are developed and proven effective, they can reach a broader patient population, increasing market penetration. Therefore, these factors will pose lucrative growth prospects for the market.
Market Restraining Factors
Challenges related to regulatory approval
Bioelectric companies looking to market their products internationally face the challenge of navigating multiple regulatory frameworks. Differences in approval processes and requirements across regions can add complexity and length to the overall regulatory timeline. Regulatory agencies may face challenges in adapting existing frameworks to accommodate rapidly evolving technologies in bioelectric medicine. The novelty and uniqueness of some bioelectric therapies may require regulatory agencies to develop specialized guidelines. These elements will hamper the growth of the market.
Type Outlook
By type, the market is bifurcated into implantable electroceutical devices and non-invasive electroceutical devices. In 2022, the non-invasive electroceutical devices segment witnessed a substantial revenue share in the market. Non-invasive electroceutical devices provide a patient-friendly alternative to invasive procedures. Patients often prefer non-invasive treatments due to reduced pain, minimal discomfort, and the absence of surgical interventions. This approach enhances patient compliance and contributes to a positive patient experience. Technological advancements have been crucial in developing sophisticated, non-invasive electroceutical devices. Innovative technologies, such as transdermal electrical stimulation and non-invasive neuromodulation, have expanded the scope of non-invasive interventions. Therefore, the segment will expand rapidly in the upcoming years.
End-use Outlook
On the basis of end-use, the market is divided into hospitals and others. The hospitals segment recorded the maximum revenue share in the market in 2022. Bioelectric interventions are finding applications across various medical specialties, ranging from neurology and pain management to cardiology and rehabilitation. The versatility of bioelectric therapies makes them relevant for addressing diverse medical conditions, prompting hospitals to explore and implement these interventions within various departments. Thus, these factors will fuel the growth of the hospitals segment.
Product Outlook
Based on product, the market is segmented into implantable cardioverter defibrillators & cardiac pacemakers, cochlear implants, spinal cord stimulators, deep brain stimulators, transcutaneous electrical nerve stimulators, sacral & vagus nerve stimulators, and others. In 2022, the spinal cord stimulators segment garnered a significant revenue share in the market. Spinal cord stimulators are often used as a therapeutic option for managing chronic pain conditions, such as failed back surgery syndrome and complex regional pain syndrome. The rising prevalence of these conditions, coupled with a growing aging population, can contribute to an increased demand for spinal cord stimulators. Therefore, the segment will expand rapidly in the coming years.
Application Outlook
Based on application, the market is divided into arrhythmia, pain management, sensorineural hearing loss, Parkinson's disease, tremor & epilepsy, depression, treatment-resistant depression, urinary & fecal incontinence, and others. In 2022, the tremor and epilepsy segment witnessed a substantial revenue share in the market. Tremors and epilepsy often involve abnormal electrical activity in the brain. Neuromodulation therapies, a significant component of bioelectric medicine, involve the use of electrical stimulation to modulate neural activity. Advances in neuromodulation technologies may lead to more effective treatments for conditions such as tremors and epilepsy. These factors will lead to rapid expansion of the segment.
Regional Outlook
By region, the market is segmented into North America, Europe, Asia Pacific, and LAMEA. The North America segment procured the highest revenue share in the market in 2022. North America, particularly the United States, has been a significant player in the healthcare industry, with a robust industry for medical technologies and innovations. The region has been at the forefront of bioelectric medicine research and development. Academic institutions, research centers, and industry collaborations often drive innovation, leading to the development of novel bioelectric therapies and devices. Thus, the segment will witness increased growth in the coming years.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Abbott Laboratories, Boston Scientific Corporation, Cochlear Ltd., LivaNova PLC, Koninklijke Philips N.V., Biotronik SE & Co. KG, Sonova Holding AG, Nevro Corporation, and electroCore, Inc.
Recent Strategies Deployed in Bioelectric Medicine Market
Mergers & Acquisition
May-2022: Medtronic plc acquired Intersect ENT, a medical technology company. This acquisition aimed to increase Medtronic's comprehensive ear, nose, and throat offering with innovative products used in sinus procedures to enhance post-operative outcomes and treat nasal polyps.
Nov-2021: Koninklijke Philips N.V. acquired Cardiology, a France-based medical technology company focused on transforming cardiac diagnostics using artificial intelligence (AI) and cloud technology. Through his acquisition, Koninklijke Philips N.V. would be able to strengthen its diagnostics offering and cardiac monitoring with electrocardiogram (ECG) analysis, creative software technology, and reporting services.
Feb-2021: Koninklijke Philips N.V. took over BioTelemetry, Inc., a leading U.S.-based provider of remote cardiac diagnostics and monitoring. Through this acquisition, Koninklijke Philips N.V. would be in a favourable position to enhance patient care across care environments for medical conditions and numerous diseases with the help of the combination of both the organization's portfolio and service platforms.
Jan-2020: Medtronic took over Stimgenics, a startup company that has developed a novel spinal cord stimulation waveform. This acquisition enabled the company to expand its business in the SCS Market.
Jun-2019: Boston Scientific acquired Vertiflex, a healthcare company. Through this acquisition, Vertiflex's spinal cord stimulation and radiofrequency ablation have been added to Boston Scientific's product portfolio.
Partnerships, Collaborations & Agreements
Nov-2021: Medtronic PLC partnered with Rune Labs, a company using aggregated brain data to empower the development and delivery of precision medicines for neurological and psychiatric diseases. This partnership aimed to assess the use of BrainSense technology, the first and only complete Deep Brain Stimulation system able to chronically capture and record brain signals.
Aug-2021: electroCore, Inc. signed an agreement with Red One Medical Devices, LLC, a service-disabled veteran-owned small business. This agreement aimed to widen the availability of electroCore's gammaCore platform in the federal marketplace.
May-2020: Medtronic collaborated with UW following which the company has accelerated research into deep brain stimulation treatment for essential tremor, Parkinson's disease, and other neurological disorders.
May-2019: Abbott came into partnership with the US National Institutes of Health (NIH). The partnership was aimed at developing unique insights and driving the application of neurostimulation therapies. The partnership would provide the latter company's neuroscience research initiative BRAIN access to Abbott's neuromodulation technologies.
Product Launches and Product Expansions
Dec-2022: electroCore, Inc. rolled out Truvaga, a new wellness product offering. The launched product aimed to provide a drug-free, simple, and convenient way to support in reducing stress with just 2-minute sessions, day and night; no apps, batteries, chargers, or phones are required.
Nov-2022: electroCore, Inc. introduced gammaCore Sapphire, the first and only FDA-cleared non-invasive device. The launch would be aimed at treating and preventing multiple types of headache pain via the vagus nerve.
Oct-2020: Abbott Laboratories introduced ICD (Implantable Cardioverter-Defibrillator), a medical device that monitors heart rhythms and delivers shocks to treat life-threatening arrhythmias, and CRT-D (Cardiac Resynchronization Therapy with Defibrillation), an ICD with an added feature to synchronize the contractions of the heart's ventricles, improving heart function in certain patients.
Jan-2020: Medtronic announced the CE mark for its Percept PC neurostimulator. This is a Deep Brain Stimulation (DBS) system with BrainSense technology. The system can sense and record brain signals while offering therapy to patients with neurologic disorders, such as Parkinson's disease.
Oct-2019: Medtronic launched Activa Programming, a new system. The system enables the patients in managing their deep brain stimulation (DBS) treatments at home using a dedicated and customized Samsung smartphone.
Jan-2019: Cochlear Ltd. launched Nucleus 7 Sound Processor, implantable hearing device for the people with single-sided deafness, conductive and mixed hearing loss.
Jan-2019: Boston launched WaveWriter Spinal Cord Stimulator (SCS) System in Europe for providing the treatment of chronic pain to people in Europe.
Jan-2019: Boston Scientific introduced the Vercise Primary Cell (PC) and Vercise Gevia Deep Brain Stimulation (DBS) Systems. The systems feature the Vercise Cartesia Directional Lead. The systems have the technology that enables the physicians in controlling the range, shape, position, and direction of electrical stimulation to treat the symptoms of Parkinson's disease (PD) through highly-personalized therapy.
Geographical Expansion
Sep-2019: Sonova opened a new training center in Germany. This expansion aimed to provide training program for hearing care professionals.
Mar-2019: Cochlear Ltd. expanded its reach to UK. This expansion aimed to provide the criteria for cochlear implant to professionals.
Approvals and Trials
Jul-2023: Abbott Laboratories got approval from the FDA for the AVEIR dual chamber (DR) leadless pacemaker system, an advanced medical device that offers dual-chamber pacing capabilities without the need for traditional leads or wires, improving patient comfort and reducing potential complications.
Oct-2022: Nevro Corporation got FDA approval for the Senza HFX iQ spinal cord stimulation (SCS) system, the first and only Artificial Intelligence-based SCS system. The approved product would address the variability in pain from patient to patient and support patients to optimize and maintain long-term pain relief and improved quality of life.
Jan-2021: Medtronic plc introduced the first enrollment in ADAPT-PD. This trial aimed to evaluate the safety and efficacy of adaptive deep brain stimulation (aDBS) in patients with Parkinson's Disease.
Jan-2020: Abbott Laboratories got approval from the US Food and Drug Administration (FDA) for its Infinity Deep Brain Stimulation (DBS) system. This system would be used in the treatment of Parkinson's disease. The system would enable targeting a specific area of the brain known as the internal globus pallidus (GPi) for improving the symptoms of Parkinson's disease not controlled by medication.
Nov-2019: Nevro Corporation received approval from the FDA for the Senza Omnia Spinal Cord Stimulation (SCS) System. The Omnia system has been designed to deliver Nevro's proprietary HF10 therapy in addition to all other available SCS frequencies.
Market Segments covered in the Report:
By Type
By End-use
By Product
By Application
By Geography
Companies Profiled
Unique Offerings from KBV Research